Table 1. Baseline characteristics of included studies.
| Study | Year | Country | Primary tumor site | Treatment regimen | No. of patients | Median age (range) | Male/ Female | performance status | Line of treatment | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| Wang Jue | 2016 | China | left-sided | Cetuximab +FOLFOX/FOLFIRI | 32 | 59 (38–76) | 22/10 | NA | First-line | ORR, PFS |
| right-sided | Cetuximab +FOLFOX/FOLFIRI | 16 | 56 (34–74) | 11/5 | NA | First-line | ORR, PFS | |||
| Feng Wang | 2015 | China | left-sided | Cetuximab +mFOLFOX-6/XELOX/ FOLFIRI | 145 | NA | 98/47 | ECOG (0/1/2): 78/61/6 | First-line/second-line | ORR, OS, PFS |
| right-sided | Cetuximab +mFOLFOX-6/XELOX/ FOLFIRI | 61 | NA | 40/21 | ECOG (0/1/2): 24/32/5 | First-line/second-line | ORR, OS, PFS | |||
| von Einem JC | 2014 | Germany | left-sided | Cetuximab + CaPIRI/ CaPOX | 100 | 63 (32–77) | 77/23 | Karnofsky > 90/70 + 80/NR): 73/25/2 | First-line/second-line | ORR, OS, PFS |
| right-sided | Cetuximab + CaPIRI/ CaPOX | 46 | 61 (47–74) | 28/18 | Karnofsky (> 90/70 + 80/NR): 32/14/0 | First-line/second-line | ORR, OS, PFS | |||
| Kuo-Hsing Chen | 2016 | China | left-sided | Cetuximab + chemotherapy | 765 | 60 (22–96) | 591/378 | NR | First-line | OS, TTD |
| right-sided | Cetuximab + chemotherapy | 136 | 60 (22–96) | NR | First-line | OS, TTD | ||||
| Rui Qin | 2014 | China | left-sided | Cetuximab +FOLFOX/FOLFIRI/XELOX | 63 | 56 (21–86) | 64/26 | NR | First-line/second-line | ORR, OS, PFS |
| right-sided | Cetuximab +FOLFOX/FOLFIRI/XELOX | 27 | 56 (21–86) | NR | First-line/second-line | ORR, OS, PFS | ||||
| Moretto R | 2016 | Italy | left-sided | anti-EGFR or cetuximab-irinotecan | 61 | NA | NA | NA | First-line/second-line | ORR, PFS |
| right-sided | anti-EGFR or cetuximab-irinotecan | 14 | NA | NA | NA | First-line/second-line | ORR, PFS | |||
| Alan P. Venook | 2016 | USA | left-sided | Cetuximab +FOLFOX/FOLFIRI | 689 | 59 | NA | NA | First-line | OS, PFS |
| right-sided | Cetuximab +FOLFOX/FOLFIRI | 342 | 59 | NA | NA | First-line | OS, PFS | |||
| Eric Van Cutsem | 2016 | Germany | left-sided | Cetuximab + FOLFIRI | 142 | 60 | NA | NA | First-line | ORR |
| right-sided | Cetuximab + FOLFIRI | 33 | 60 | NA | NA | First-line | ORR | |||
| Heinemann V | 2014 | multi-center | left-sided | Cetuximab + FOLFIRI | 157 | NA | NA | NA | Second-line | PFS, OS |
| right-sided | Cetuximab + FOLFIRI | 38 | NA | NA | NA | Second-line | PFS, OS | |||
| Yu Sunakawa | 2016 | Japan | left-sided | Cetuximab + FOLFOX/SOX | 90 | NA | NA | NA | First-line | ORR, OS, PFS |
| right-sided | Cetuximab + FOLFOX/SOX | 20 | NA | NA | NA | First-line | ORR, OS, PFS |
Abbreviations: TTD, time to treatment discontinuation; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; RCC, right-sided colon cancer; LCRC, left-sided colorectal cancer; BSC, Best supportive care; ORR, overall response rate; DFS, disease free survival; PFS, progression free survival; NA, not available; NR, not reported; WHO, world health organization; PS, performance status; EGFR, epidermal growth factor receptor.